PR Newswire All News ReleasesCodex · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 04:22:00·⟳ 抓取 04:23:05 +1m05s·⚡ 决策 08-28 13:54:58 +9h31m·60.1 天前
Pomerantz再次发布EyePoint投资者索赔调查提醒，核心事实仍是8月17日DURAVYU三期未达主终点
同一Pomerantz投资者调查提醒已在2026-08-25和2026-08-26由其它新闻源发布，本次PR Newswire稿没有新增官方确认、诉讼阶段、金额、监管进展或公司回应；核心临床失败和股价大跌已是8月17日旧事实。
📄 原文PR Newswire All News Releases↗ 原文
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc.…
不做 EyePoint Pharmaceuticals（EYPT.US）
不做EyePoint Pharmaceuticals（EYPT.US）：本条是重复律所调查广告，核心临床失败已在8月17日披露并引发约67%单日下跌，8月27日没有新增诉讼、监管或公司确认事实；做空缺少新强催化，做多缺少反转事实。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
这不是新的临床、监管或诉讼进展，而是律所围绕EyePoint 8月17日DURAVYU三期未达主终点后的股价下跌重复招揽投资者。EyePoint（EYPT.US）8月17日已从14.75美元附近跌至4.87美元，8月27日收4.63美元，负面信息已充分扩散并被价格吸收；做空缺少新增强催化，做多也没有反转性事实。
消息传播链
- EyePoint首次披露LUGANO三期完整数据集未达主要终点，同时称剔除4%非湿性AMD相关视力下降患者的事后分析显示非劣效。市场反应:EYPT 2026-08-17收盘较前一交易日下跌66.98%，收4.87美元。
- EyePoint向SEC提交8-K确认LUGANO三期顶线数据披露。
- Pomerantz已发布同一EyePoint投资者调查提醒，内容与8月27日PR Newswire稿实质一致。
- 同一律所调查提醒再次发布，未新增诉讼、监管或公司回应事实。
- 本次抓取稿为同一Pomerantz调查广告的PR Newswire版本，未见新增事实。市场反应:EYPT 8月27日收4.63美元，较前收跌约7.21%。
关键理由
- 本条新增事实仅为Pomerantz重复发布投资者调查广告，不改变EyePoint临床失败后的基本面判断。
- DURAVYU LUGANO完整数据集未达主要终点已在2026-08-17由公司和SEC 8-K披露，当日股价已暴跌约67%。
- 8月25日、8月26日已有同类Pomerantz调查提醒传播，8月27日PR Newswire版本没有可交易的新信息差。
主要风险
- 若后续出现正式集体诉讼立案、SEC调查、公司承认披露问题或第二个三期试验也失败，EyePoint仍可能继续承压。
- 若第二个关键三期试验在四季度读出明显正面结果，当前临床失败叙事可能被部分逆转。
反向证据
- 做空前查反向 · 来源 web · 日期 2026-08-17 · 影响 weakens
EyePoint称LUGANO虽完整数据集未达主要终点，但事后剔除异常队列后显示非劣效，并预计第二个三期四季度读出、H1 2027潜在提交，削弱把重复律所广告作为新增强空催化的力度。
检索:EyePoint DURAVYU second Phase 3 Q4 2026 regulatory submission H1 2027 positive secondary endpoints 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-08-25 · 影响 invalidates
8月25日已有同一Pomerantz调查提醒，说明8月27日版本不是新鲜反转利好，也不能支持做多。
检索:EyePoint Pomerantz investigation duplicate investor alert August 25 August 27 2026 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足未改变结论；决定性因素是同一调查提醒已提前两日出现且核心临床失败已于8月17日完成大幅重定价。
方向:律所重复调查广告通常弱于原始临床失败或正式诉讼进展，不能单独支持新的做空交易。
涨幅量级:未使用外部事件研究幅度校准，因为本次在去重和传播链核验后已判定为无新增事实的重复提醒。
形态:本次可迁移的核心模式是重复投资者提醒缺少新增基本面或法律进展，主要风险已在原始负面事件当日定价。
原文全文
展开原文 · 1,881 字
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ: EYPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether EyePoint and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On August 17, 2026, EyePoint issued a press release "announc[ing] topline results from LUGANO, the first pivotal Phase 3 clinical trial for DURAVYU™ (vorolanib intravitreal insert) for the treatment of wet age-related macular degeneration (wet AMD)." The press release disclosed that change from baseline in best corrected visual acuity versus 2 mg aflibercept (Regeneron Pharmaceuticals' (REGN) Eylea) was not met in the entire dataset.
On this news, EyePoint's stock price fell $9.88 per share, or 66.98%, to close at $4.87 per share on August 17, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980
SOURCE Pomerantz LLP
The investigation concerns whether EyePoint and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On August 17, 2026, EyePoint issued a press release "announc[ing] topline results from LUGANO, the first pivotal Phase 3 clinical trial for DURAVYU™ (vorolanib intravitreal insert) for the treatment of wet age-related macular degeneration (wet AMD)." The press release disclosed that change from baseline in best corrected visual acuity versus 2 mg aflibercept (Regeneron Pharmaceuticals' (REGN) Eylea) was not met in the entire dataset.
On this news, EyePoint's stock price fell $9.88 per share, or 66.98%, to close at $4.87 per share on August 17, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980
SOURCE Pomerantz LLP
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。